These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31205516)

  • 1. The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Yoon SE; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
    J Cancer; 2019; 10(7):1611-1615. PubMed ID: 31205516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
    Kazaz SN; Ozdover AC; Usta N; Yildirim A; Fidan E; Ozdemir F
    J Coll Physicians Surg Pak; 2023 Jun; 33(6):659-665. PubMed ID: 37300262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Kim ST; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS
    J Cancer; 2017; 8(14):2809-2815. PubMed ID: 28928870
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparison of clinicopathological features and prognosis between left-sided colon cancer and right-sided colon cancer].
    Gao X; Yu G; Liu P; Hao L; Liu L; Zhang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):647-653. PubMed ID: 28643309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.
    Kim ST; Kim HK; Lee J; Park SH; Lim HY; Park YS; Kang WK; Park JO
    J Cancer; 2018; 9(10):1791-1796. PubMed ID: 29805705
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
    Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; Ronzoni M; Racca P; Loupakis F; Zaniboni A; Tonini G; Buonadonna A; Marmorino F; Allegrini G; Granetto C; Masi G; Zagonel V; Sensi E; Fontanini G; Boni L; Falcone A
    Ann Oncol; 2018 Jul; 29(7):1528-1534. PubMed ID: 29873679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
    Brulé SY; Jonker DJ; Karapetis CS; O'Callaghan CJ; Moore MJ; Wong R; Tebbutt NC; Underhill C; Yip D; Zalcberg JR; Tu D; Goodwin RA
    Eur J Cancer; 2015 Jul; 51(11):1405-14. PubMed ID: 25979833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
    Sun Z; Wang X; Jia J; Liu C; Zhang X; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1119-1123. PubMed ID: 27781247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
    Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
    World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
    Archwamety A; Teeyapun N; Siripoon T; Poungvarin N; Tanasanvimon S; Sirachainan E; Akewanlop C; Korphaisarn K
    Front Oncol; 2022; 12():813009. PubMed ID: 35242708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis.
    Azar I; Al Masalmeh N; Esfandiarifard S; Virk G; Kiwan W; Frank Shields A; Mehdi S; Philip PA
    Cancer Med; 2021 May; 10(9):2987-2995. PubMed ID: 33797856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
    Salvatore L; Bensi M; Vivolo R; Zurlo IV; Dell'Aquila E; Grande R; Anghelone A; Emiliani A; Citarella F; Calegari MA; Ribelli M; Basso M; Pozzo C; Tortora G
    Front Oncol; 2023; 13():1125013. PubMed ID: 36895480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
    Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
    Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment.
    Lee MS; Cho HJ; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Cho YB; Kim ST
    Ther Adv Med Oncol; 2020; 12():1758835920965842. PubMed ID: 33224274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.
    Ma CJ; Huang CW; Chang TK; Tsai HL; Su WC; Yeh YS; Chen PJ; Wang JY
    Transl Oncol; 2019 Mar; 12(3):502-512. PubMed ID: 30594039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study.
    Shida D; Tanabe T; Boku N; Takashima A; Yoshida T; Tsukamoto S; Kanemitsu Y
    Ann Surg Oncol; 2019 May; 26(5):1358-1365. PubMed ID: 30719633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of raltitrexed plus S-1
    Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
    Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.